Preveceutical Medical

Preveceutical Medical FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Preveceutical Medical (PREV.CN) as of Nov 7, 2026 is 15.03 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 27.89 % — a change of -46.13% (lower).

FCF Conversion

15.03 %

YoY

-46.13%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Preveceutical Medical is 2022 15.03 % . FCF Conversion Rate (FCF/EBITDA) of Preveceutical Medical was 2021 27.89 % . It decreases by -46.13% lower compared to the previous year.

The Preveceutical Medical FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
54.95 CAD
Jan 1, 2017
62.11 CAD
Jan 1, 2018
63.81 CAD
Jan 1, 2019
27.81 CAD
Jan 1, 2020
-1.63 CAD
Jan 1, 2021
27.89 CAD
Jan 1, 2022
15.03 CAD
The Preveceutical Medical FCF Conversion history
YEARFCF ConversionYoY
15.03 %-46.13%
27.89 %-1,812.83%
-1.63 %-105.86%
27.81 %-56.42%
63.81 %+2.74%
62.11 %+13.03%
54.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Preveceutical Medical Stock analysis

What does Preveceutical Medical do? Preveceutical Medical Inc, based in Vancouver, Canada, specializes in licensing, branding, and marketing nutraceutical and wellness products. The company, listed on 30 December 2016, focuses on developing preventive and curative therapies using organic and nature-identical products. Its pipeline includes a cannabinoid-based nose-to-brain delivery system for pain and neurological conditions, a non-addictive analgesic peptide for pain management, a BSV peptide program targeting cancer, and dual gene therapy for type 2 diabetes and obesity. The company operates through its subsidiary in Australia for research management. Preveceutical Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Preveceutical Medical stock

FCF Conversion Rate (FCF/EBITDA) of Preveceutical Medical is 15.03 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of Preveceutical Medical changed from 27.89 % to 15.03 %, representing a -46.13% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Preveceutical Medical since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Preveceutical Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Preveceutical Medical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Preveceutical Medical